Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.
J Infect Dis. 2022 Oct 17;226(8):1396-1400. doi: 10.1093/infdis/jiac358.
After >2 years of the coronavirus disease 2019 (COVID-19) pandemic, immunoglobulins (IGs) contain highly potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, based on the large proportion of United States (US) plasma donors who have gone through COVID-19 or vaccination against the virus. Neutralization of Omicron SARS-CoV-2 by antibodies generated after non-Omicron infection or vaccination has been lower though, raising concerns about the potency of IG against this new virus variant. Also, as plasma collected in the US remains the main source of IG, the neutralization of SARS-CoV-2 for plasma collected elsewhere has been less well studied. Here, we confirm Omicron neutralization by US as well as European Union plasma-derived IG lots.
在 2019 年冠状病毒病(COVID-19)大流行超过 2 年后,基于美国(美国)大量经历过 COVID-19 或接种过该病毒疫苗的血浆供体,免疫球蛋白(IG)含有高浓度的强效严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)中和抗体。然而,非奥密克戎感染或接种疫苗后产生的抗体对奥密克戎 SARS-CoV-2 的中和作用较低,这引发了对 IG 针对这种新病毒变体效力的担忧。此外,由于在美国采集的血浆仍然是 IG 的主要来源,因此对其他地方采集的血浆中 SARS-CoV-2 的中和作用研究较少。在这里,我们证实了来自美国和欧盟的血浆衍生 IG 批次对奥密克戎的中和作用。